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Background: Consensus guidelines recommend early treatment to eradicate newly acquired Pseudomonas aeruginosa (Pa) infection in cystic
ﬁbrosis (CF) patients although there is no single preferred regimen. Aztreonam for inhalation solution (AZLI) signiﬁcantly reduces sputum Pa
density in CF patients with chronic Pa infection and has been well tolerated in the pediatric population. This single-arm, open-label Aztreonam
Lysine for Pseudomonas Infection Eradication (ALPINE) study was conducted to evaluate the safety and efﬁcacy of a 28-day treatment course of
AZLI to eradicate newly acquired Pa infection in pediatric CF patients.
Methods: CF patients (3 months to b18 years) with new onset Pa infection were treated with AZLI 75 mg 3 times daily for 28 days. New
onset Pa infection was deﬁned as ﬁrst lifetime Pa-positive respiratory tract culture (throat swab, sputum) or Pa-positive culture after a ≥2-year
history of Pa-negative cultures (≥2 cultures/year). Sputum or throat swab cultures were collected at study entry (baseline) and at weeks
4 (end of treatment), 8, 16, and 28. Primary endpoint was the percentage of patients with cultures negative for Pa at all post-treatment time
points.
Results: A total of 105 pediatric CF patients enrolled (3 months to b2 years, n = 24; 2 to b6 years, n = 25; 6 to b18 years, n = 56). Of the 101
patients who completed treatment, 89.1% (n = 90) were free of Pa at the end of treatment and 75.2% (n = 76) were free of Pa 4 weeks after the
end of treatment. Of the 79 patients evaluable for the primary endpoint, 58.2% were free of Pa at all post-treatment time points.
Conclusions: AZLI was effective and well tolerated in eradicating Pa from newly infected pediatric patients with CF. These eradication
rates are consistent with success rates reported in the literature for various antibiotic regimens, including other inhaled antibiotics studied for
eradication.
ClinicalTrials.gov: NCT01375049.
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Patients with cystic fibrosis (CF) are susceptible to pulmonary
infections with pathogenic microorganisms and acquisition ofis Society.
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course [1–3]. Aggressive treatment of initial Pa infection delays
progression to chronic infection, which is associated with
increased morbidity and mortality in children with CF [2,3].
End-of-treatment eradication rates of 74–100% have been
observed for various antibiotic regimens [3–18]. Eradication at
initial Pa detection is recommended by consensus treatment
guidelines and is now a treatment strategy used by most CF
centers [19,20].
Aztreonam for inhalation solution (AZLI; Cayston®; Gilead
Sciences), a lyophilized formulation of the monobactam antibiotic
aztreonam, improves respiratory symptoms, delays time to need
for additional antibiotics, reduces sputum Pa density in CF
patients with chronic infection, and is well tolerated in the pediatric
population (6–17 years of age) [21–24]. These findings provided
the rationale for the Aztreonam Lysine for Pseudomonas Infection
Eradication (ALPINE) study, which evaluated the safety and
efficacy of a 28-day course of AZLI to eradicate new onset Pa
infection in children with CF throughout a 24-week follow-up
period.
2. Methods
2.1. Study design
This open-label, multicenter study was conducted at 46 CF
centers (Europe: 23; US: 23; Oct 2011–May 2013). Eligible
patients received 28 days of AZLI 75 mg three times daily,
administered via the PARI Investigational eFlow® Nebulizer
System, with the SmartMask® Baby for patients b2 years of age,
the SmartMask Kids for patients 2 to b6 years, or the nebulizer
mouthpiece for patients ≥6 years. Using these age criteria as
guidelines, investigators determined the best method of admin-
istering AZLI. A short-acting bronchodilator was administered
approximately 1 h before AZLI. Study visits included screening,
baseline (day 1), week 4 (day 28), and weeks 8, 16, and 28
(during the 24-week follow-up period).
Study-related microbiology assessments were performed at a
central laboratory. Pa culture results from local laboratories were
not monitored except to assess study entry criteria and define
infection history. Patients receiving additional (non-study) anti-
pseudomonal antibiotics during the study were withdrawn from
study assessments (discontinued), but followed until ongoing
adverse events resolved.
2.2. Patients
Eligible patients were clinically stable, 3 months to b18 years
of age, with documented CF, FEV1≥80% predicted at screening
(for patients ≥6 years), and newly detected Pa respiratory tract
infection within 30 days of screening (expectorated sputum or
throat swab; cultured at local laboratories), defined as either first
lifetime documented culture positive for Pa or first positive
culture after ≥2 year history of ≥2 negative cultures/year.
Key exclusion criteria included the use of intravenous or
inhaled anti-pseudomonal antibiotics (within 2 years before
screening); oral anti-pseudomonal antibiotics (30 days beforescreening); hospitalization for pulmonary-related illness (28 days
before screening); and other conditions potentially interfering
with study participation/safety, in the opinion of the Investigators.
The study was conducted in accordance with the principles of
the Declaration of Helsinki (as amended in Edinburgh, Tokyo,
Venice, Hong Kong, and South Africa), International Conference
on Harmonisation guidelines, good clinical practice principles,
and detailed guidelines in line with those principles. The study
was approved by Institutional Review Boards or Independent
Ethics Committees for each site. Patients and/or parents/guardians
provided written informed consent before any study-related
procedures.
2.3. Measures
The primary endpoint was the proportion of patients with
cultures negative for Pa at all visits throughout the 24-week
follow-up period. Subgroup analyses evaluated age, gender, Pa
infection history (first lifetime/recurrence), baseline culture results
(Pa negative/positive), and baseline anti-pseudomonal antibodies
(negative/positive).
Secondary endpoints included proportion of patients with
cultures negative for Pa at each follow-up visit, additional anti-
pseudomonal antibiotic use, and for patients ≥6 years, changes
from baseline in FEV1 % predicted and Cystic Fibrosis
Questionnaire-Revised Respiratory Symptoms Scale (CFQ-R-
RSS) scores [25].
Other endpoints of interest included isolation of other
respiratory pathogens, changes in minimum inhibitory concentra-
tion (MIC) of aztreonam for Pa, and Pa-specific serum antibodies
(enzyme immunoassay, Mediagnost, Reutlingen Germany).
Aztreonam plasma concentrations were measured for patients
b6 years old. The genetic relatedness of Pa strains isolated at
baseline and during follow-up for individual patients was
compared by pulsed-field gel electrophoresis (PFGE) [26].
Safety endpoints included monitoring adverse events, airway
reactivity (study drug-induced bronchospasm), vital signs,
hospitalizations, and clinical laboratory analyses (biochemistry;
hematology).
2.4. Statistics
The safety analysis set included all AZLI-treated patients. The
primary efficacy evaluable set included patients completing
the 28-day course of AZLI without receiving additional anti-
pseudomonal antibiotics, who either completed all follow-up
visits through week 28 with cultures negative for Pa at every visit
without the use of additional anti-pseudomonal antibiotics
(successful treatment), or had a study-related culture positive
for Pa at any follow-up visit (treatment failure). Patients who
used additional anti-pseudomonal antibiotics during the follow-
up period without study-related cultures positive for Pa had been
discontinued from the study and were not included in the primary
efficacy evaluable set. These patients were included in a
sensitivity analysis set and were considered treatment failures.
The sensitivity analysis resulted in a decrease in the percentage of
patients who met the primary eradication endpoint due to the
Table 1
Patient disposition and derivation of efficacy analysis populations.
Patient disposition
Screened, a n 109
Enrolled and treated, n 105
AZLI treatment status b
Completed 4 weeks of AZLI treatment, n (%) 101 (96.2)
Discontinued from AZLI treatment, n (%) 4 (3.8)
Adverse event 2 (1.9)
Non-compliance with dosing 1 (1.0)
Withdrew consent 1 (1.0)
Study completion status b
Completed study, n (%) 55 (52.4)
Discontinued from study (per protocol or other criteria),
n (%)
50 (47.6)
Protocol-specified criteria for withdrawal: positive c
P. aeruginosa culture
30 (28.6)
Positive culture with the use of additional
anti-pseudomonal antibiotics
26
Positive culture without the use of additional
anti-pseudomonal antibiotics
4
Protocol-specified criteria for withdrawal: the use
of additional anti-pseudomonal antibiotics without
positive c P. aeruginosa culture
15 (14.3)
During 4-week treatment period 1
During follow-up period (weeks 4 through 28) 14
Adverse event 2 (1.9)
Withdrew consent 2 (1.9)
Lost to follow-up 1 (1.0)
Derivation of efficacy analysis populations n
Enrolled and treated 105
Did not complete treatment b (4)
Completed 28 days of AZLI treatment 101
Missing P. aeruginosa culture data during follow-up period d (3)
Sensitivity analysis set 98
Received additional anti-pseudomonal antibiotics without
evidence of positive P. aeruginosa culture c,e
(19)
Efficacy evaluable set for primary endpoint 79
a Reasons for failing screening included not meeting all inclusion criteria
(n = 1), meeting 1 or more of the exclusion criteria (n = 3), and/or withdrawal
of consent (n = 1).
b Reasons for discontinuing AZLI treatment differed from reasons for
discontinuing the study for 3 patients: 1 patient withdrew from treatment due to
an adverse event and withdrew from the study due to protocol-specified criteria
(the use of additional antibiotics without positive P. aeruginosa culture during
the 4-week treatment period); 1 patient withdrew from treatment due to non-
compliance with dosing and withdrew consent for the study, and 1 patient
withdrew consent for treatment and withdrew from the study due to protocol-
specified criteria (the use of additional antibiotics without positive P. aeruginosa
culture during follow-up period). The fourth patient who discontinued AZLI
treatment discontinued from the study due to an adverse event.
c Based on central laboratory P. aeruginosa culture results.
d Two of the 3 patients with missing P. aeruginosa culture data completed the
study and 1 discontinued from the study due to withdrawal of consent.
e The 19 patients who were included in the sensitivity analysis set but excluded
from the efficacy evaluable set due to receipt of additional anti-pseudomonal
antibiotics without a positive P. aeruginosa culture were recorded as discontinuing
from the study due to: protocol-specified criteria: 15 (the use of additional anti-
pseudomonal antibiotics without a positiveP. aeruginosa culture); completed study:
3 (although they did use additional anti-pseudomonal antibiotics), and adverse
event: 1.
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of the analysis.
Observed changes in FEV1 % predicted (Wang pediatric
equations [27]), summarized by patients who did/did not meet
the sensitivity analysis endpoint, are reported. CFQ-R analyses
used mixed-effect model repeated measure (MMRM) methods,
including baseline value and visit in the model. Missing
baseline data were not imputed.
Assuming an eradication rate of 0.8 over the 24-week
follow-up period, a sample size of 60 evaluable patients was
considered sufficient to estimate the proportion of patients with
cultures negative for Pa to within 0.1, using a 95% confidence
interval (CI). Assuming a non-evaluable rate of ~45%, 105
patients were to be enrolled.
3. Results
3.1. Disposition and demographics
Overall, 105 patients receivedAZLI treatment (Europe: 49; US:
56), with 101 completing the 4-week treatment course (Table 1).
Reasons for discontinuing treatment were adverse event (n = 2),
dosing non-compliance (n = 1), and withdrawal of consent
(n =1). The most common reason for study discontinuation
was meeting protocol-specified criteria (n = 45: culture-positive
for Pa [n = 30]; the use of additional anti-pseudomonal antibiotics
without being culture-positive [n = 15]).
Overall, 22.9% of patients were 3 months to b2 years,
23.8% were 2 to b6 years, and 53.3% were 6 to b18 years of
age (Table 2). Most patients were white (94.3%; n = 99/105) and
55.2% (n = 58) were female. The positive culture documented
within 30 days before screening was the first lifetime Pa
infection for 70.5% of patients (n = 74/105). At baseline, cultures
(performed at a central laboratory) were positive for Pa in 44.1%
of patients (n = 45/102), using expectorated sputum specimens
(63.6% patients; n = 14/22) or throat swabs (38.8%; n = 31/80).
For patients ≥6 years old (n = 56), median FEV1 was 95.4%
predicted (range: 71.1–135.4) at baseline and median CFQ-R-
RSS scores were 75.0 (range: 33.3–100). Most patients (96.2%;
n = 101/105) used ≥90% of expected AZLI vials.
3.2. Efficacy
Of 79 patients in the primary efficacy evaluable set (Table 1),
46 patients (58.2%; 95% CI: 47.4%, 69.1%) remained culture-
negative for Pa throughout the 24-week follow-up period
(Table 3). Subgroups with notably lower percentages of patients
meeting the primary endpoint included patients Pa culture-
positive at baseline (36.7%met endpoint; n = 11/30) and patients
with anti-pseudomonal antibodies at baseline (35.7% met
endpoint; n = 5/14; Table 3). A higher percentage of patients
experiencing their first lifetime Pa infection met the primary
endpoint (62.5%; n = 35/56) compared to those with recurrent
infection (47.8%; n = 11/23). In an exploratory analysis of
outcomes by region, a smaller proportion of European patients in
the primary efficacy analysis set met the primary efficacy
endpoint, compared with US patients (46%; n = 18/39 vs. 70%;n = 28/40). However, when baseline Pa-culture positivity was
examined, a higher percentage of European patients in the
sensitivity analysis set were Pa-culture positive at baseline,
Table 2
Baseline characteristics.
Characteristic AZLI (N = 105)
Age, years; mean (SD) 6.26 (4.74)
Age; range 3 months–16 years
Age group; n (%) 3 months to b2 years 24 (22.9)
2 to b6 years 25 (23.8)
6 to b18 years 56 (53.3)
Gender; n (%) Female 58 (55.2)
Male 47 (44.8)
Race; n (%) Asian, or Black or African Heritage 2 (1.9)
White 99 (94.3)
Other or not provided 4 (3.8)
Ethnicity; n (%) Hispanic 5 (4.8)
Not Hispanic 93 (88.6)
Not permitted 7 (6.7)
BMI, kg/m2; median (range) 16.4 (12.0, 30.0)
BMI, z scores, mean (SD) 0.5 (1.3)
Received P. aeruginosa vaccination, yes; n (%) 1 (1.0)
Infection history; n (%) First P. aeruginosa infection 74 (70.5)
Recurrence of P. aeruginosa infection 31 (29.5)
1 infection 16 (51.6)
3 infections 5 (16.1)
4 infections 5 (16.1)
≥5 infections 5 (16.1)
P. aeruginosa baseline culture result; a,b n (%) Negative 57 (55.9)
Positive 45 (44.1)
Non-mucoid 40 (88.9)
Mucoid 5 (11.1)
Highest aztreonam MIC ≤2 μg/mL 7 (15.6)
Highest aztreonam MIC 4–8 μg/mL 38 (84.4)
MIC of aztreonam for all P. aeruginosa isolates; c μg/mL MIC50 4
MIC90 8
Log10 P. aeruginosa CFU/g sputum;
d mean (SD) 4.6 (1.2)
Antibodies to P. aeruginosa at baseline; a,e n (%) Negative 64 (62.7)
Borderline 20 (19.6)
Positive 18 (17.6)
Baseline medications; n (%) Azithromycin 12 (11.4)
Dornase alfa 60 (57.1)
Hypertonic saline 35 (33.3)
a Data available for 102 patients.
b P. aeruginosa positive culture within 30 days before screening was required for study entry.
c 56 isolates from 45 patients with P. aeruginosa cultures positive at baseline; the concentration inhibiting growth of 50% of the isolates was the MIC50 and the
concentration inhibiting growth of 90% of the isolates was the MIC90.
d Data available for 9 patients.
e Serum samples were diluted serially (eg, 1:2, 1:4, 1:8) and tested for the presence of IgG antibodies to P. aeruginosa (enzyme immunoassay; Mediagnost,
Reutlingen, Germany); samples with no antibodies detectable at dilutions through 1:256 (ie, titer b 500) were considered negative, titers ≥500 to b1250 were
considered borderline, and titers ≥1250 to b10,000 were considered positive. Three antigens (alkaline protease, elastase, and endotoxin A) were tested for each
patient and the highest titer for each patient was used to categorize the presence/absence of antibodies.
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This difference in Pa-culture positivity could be confounding the
primary efficacy results by region, since overall, fewer patients
with a positive Pa-culture at baseline met the primary eradication
endpoint (Table 3).
The sensitivity efficacy analysis set included 19 additional
patients without study-related cultures positive for Pa, but who
used additional anti-pseudomonal antibiotics during the follow-
up period, presumably due to disease progression or local
microbiology laboratory results (Table 1); 46.9% (n = 46/98)
of these patients met the primary efficacy endpoint (Table 3).
Of the 101 patients who completed 4 weeks of AZLI treatment,
89.1% had cultures negative for Pa at week 4, and 75.2%, 63.4%,and 47.5% were culture-negative at weeks 8, 16, and 28,
respectively (Table 4). In subgroup analyses, the percentages of
patients with cultures negative for Pa at week 8, 16, or 28 were
significantly higher for patients who were culture-negative at
baseline compared with patients who were culture-positive
(Table 4). No significant differences were observed by age group
or baseline anti-pseudomonal antibodies (negative/positive).
In an exploratory analysis, Pa culture-negative rates were
assessed for a subset modeled after analyses from an eradication
study of tobramycin inhalation solution (TIS) [14]. This subset
included patients without detectable anti-pseudomonal antibodies
at baseline who completed 4 weeks of AZLI treatment (n = 62;
Online Table 3). Forty-nine of these 62 patients (79.0%) were
Table 3
Efficacy results.
Patient group Total no. in group Met primary a efficacy endpoint; n (%) 95% CI (%)
Efficacy evaluable set b 79 46 (58.2) 47.4 to 69.1
Subgroups
Age
3 months to b2 years 19 11 (57.9) 35.7 to 80.1
2 years to b6 years 18 10 (55.6) 32.6 to 78.5
6 years to b18 years 42 25 (59.5) 44.7 to 74.4
Gender
Female 42 26 (61.9) 47.2 to 76.6
Male 37 20 (54.1) 38.0 to 70.1
P. aeruginosa infection history
First infection 56 35 (62.5) 49.8 to 75.2
Recurrent infection 23 11 (47.8) 27.4 to 68.2
P. aeruginosa baseline culture result c
Negative 47 34 (72.3) 59.6 to 85.1
Positive 30 11 (36.7) 19.4 to 53.9
Antibodies to P. aeruginosa d
Antibody negative 51 34 (66.7) 53.7 to 79.6
Antibody borderline 12 6 (50.0) 21.7 to 78.3
Antibody positive 14 5 (35.7) 10.6 to 60.8
Sensitivity analysis set e 98 46 (46.9) 37.1 to 56.8
a Patients with cultures that were negative for P. aeruginosa at every visit from weeks 4 through 28 and did not use additional anti-pseudomonal antibiotics were
considered to have met the primary endpoint.
b The evaluable analysis set (see Table 1) included patients who completed the 28-day course of AZLI, did not receive additional anti-pseudomonal antibiotics
during the treatment period, and either completed the study follow-up period through week 28 with P. aeruginosa-negative cultures at every visit and without the use
additional anti-pseudomonal antibiotics or had evidence of a positive P. aeruginosa culture during the follow-up period.
c Data available for 77 patients.
d Method and titers used to categorize responses are described in footnote e of Table 2.
e The sensitivity analysis set differed from the evaluable analysis set (see Table 1) by including patients who used additional anti-pseudomonal antibiotics during
the follow-up period without study-related cultures positive for Pa; these patients were censored from the primary analysis and considered treatment failures in the
sensitivity analysis.
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Online Table 4). For these 49 patients, 85.7%, and 71.4% were
culture-negative for Pa at weeks 16 and 28, respectively.Table 4
Patients who were Culture-Negative for P. aeruginosa by Visit.
N
All patients completing the 28-day treatment period 101
Subgroups
Age 3 months to b2 years 23
2 to b6 years 24
6 to b18 years 54
P. aeruginosa infection history First 71
Recurrent 30
P. aeruginosa culture at baseline a Positive 42
Negative 56
P. aeruginosa phenotype at baseline b Mucoid 3
Non-mucoid 39
Antibodies to P. aeruginosa at baseline a,c Negative 62
Borderline 19
Positive 17
P-values noted for descriptive comparisons between subgroups where significant, u
EOT = end of treatment.
a Baseline data missing for 3 patients.
b P. aeruginosa phenotype determined for 42 positive baseline cultures.
c Method and titers used to categorize responses are described in footnote e of TaPatients ≥6 years old in the sensitivity analysis set who met
the primary endpoint (n = 25), had FEV1% predicted remain near
baseline until week 16, with a 2.5% mean actual decrease fromPatients culture-negative for P. aeruginosa; n (%)
Week 4 (EOT) Week 8 Week 16 Week 28
90 (89.1) 76 (75.2) 64 (63.4) 48 (47.5)
20 (87.0) 17 (73.9) 14 (60.9) 12 (52.2)
23 (95.8) 19 (79.2) 15 (62.5) 10 (41.7)
47 (87.0) 40 (74.1) 35 (64.8) 26 (48.1)
63 (88.7) 55 (77.5) 47 (66.2) 37 (52.1)
27 (90.0) 21 (70.0) 17 (56.7) 11 (36.7)
36 (85.7) 23 (54.8) 18 (42.9) 11 (26.2)
52 (92.9) 50 (89.3) 43 (76.8) 35 (62.5)
p b 0.001 p = 0.005 p = 0.004
3 (100) 3 (100) 1 (33.3) 1 (33.3)
33 (84.6) 20 (51.3) 17 (43.6) 10 (25.6)
57 (91.9) 49 (79.0) 42 (67.7) 35 (56.5)
17 (89.5) 13 (68.4) 11 (57.9) 6 (31.6)
15 (88.2) 12 (70.6) 9 (52.9) 5 (29.4)
sing Fisher's exact test.
ble 2.
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endpoint (n = 27), corresponding decreases in observed values
were 4.2%, 5.1%, and 8.9%, at weeks 8, 16, and 28, respectively.
Mean changes in CFQ-R RSS for the patients in the sensitivity
analysis set who met the primary eradication endpoint (n = 25)
were numerically higher or similar to patients who did not meet
the endpoint (n = 31), with mean changes above the minimum
important difference score for stable patients (4.0 points [28]) at
all but 1 time point (week 16 for patients who did not meet the
primary endpoint; Online Fig. 1).
3.3. Plasma concentrations
For patients b6 years old (n = 49), median (range) aztreonam
plasma concentrations were 405 (84–2550) ng/mL, 1 h after
the first AZLI dose (day 1; n = 40) and 79 (1–741) ng/mL,
immediately before the last dose (day 28; n = 43). Median
(range) aztreonam plasma concentrations were comparable for
patients 3 months to b2 years (n = 24; 355 [84–2550] and 92
[1–741] ng/mL at days 1 and 28, respectively; n = 21 with data)
and patients 2 years to b6 years (n = 25; 466 [96–1880] and 43
[1–711] ng/mL at days 1 and 28, respectively; n = 19 and 22
with data).
3.4. Safety
Treatment emergent events included those occurring during
or within 30 days after AZLI treatment. The most commonly
reported treatment-emergent adverse events were cough (41.0%,
n = 43/105), pyrexia (14.3%, n = 15/105), and rhinorrhea (9.5%,
n = 10/105); these events were also the most common events
during the follow-up period (Online Table 1). Cough (14.3%,
n = 15/105) was the only treatment-related adverse event
reported for N1 patient. Adverse event terms corresponding to
decreased pulmonary function and shortness of breath were
pooled; such events were experienced by 5 (4.8%) and 2 (1.9%)
patients, respectively. For the majority of patients with serious
adverse events during the study, such events were due to
worsening CF symptoms that led to hospitalization. A ≥15%
decrease in FEV1 was observed 30 min after in-clinic AZLIFig. 1. Change in FEV1 % predicted. Actual change from baseline FEV1 %
predicted for patients ≥6 years of age in the sensitivity analysis set (n = 52),
who met (n = 25) or did not meet (n = 27) the primary study efficacy endpoint.treatment for 2 patients ≥6 years old (baseline: n = 1; week 4:
n = 1).
Two patients discontinued AZLI treatment due to adverse
events; events were considered AZLI treatment-related for 1
patient (3 months of age; dyspnea, cough, agitation, and post-
tussive vomiting, study day 1).
Overall, 16.2% (n = 17/105) of patients were hospitalized at
least once during the study, with 10.5% (n = 11/105) hospital-
ized for respiratory events (identified by study medical monitor);
most of these (n = 9/11) occurred during the follow-up period
(Online Table 2).
3.5. Microbiology
The aztreonamMIC50 andMIC90 for all 56 baselinePa isolates
were 4 and 8 μg/mL, respectively, and remained unchanged
(≤2-fold) for the 50 isolates obtained from later visits during the
study. No baseline isolates had an aztreonam MIC N8 μg/mL
(established parenteral susceptibility breakpoint); such isolates
were observed for 2 patients each at weeks 4 and 8. The MIC50
and MIC90 of cefepime, ceftazidime, meropenem, piperacillin,
piperacillin/tazobactam, ticarcillin/clavulanate, and tobramycin
remained unchanged (≤2-fold) from baseline during the
study. The MIC90 of amikacin increased 4-fold from baseline in
week 4 Pa isolates (to 16 μg/mL; n = 11 isolates) and the MIC90
for ciprofloxacin increased 16-fold from baseline at week 16 (to
4 μg/mL; n = 14 isolates). No concerning changes were observed
in the presence of other respiratory pathogens (Achromobacter,
Burkholderia, or Aspergillus spp., Haemophilus influenzae,
Stenotrophomonas maltophilia, or methicillin-sensitive or
methicillin-resistant Staphylococcus aureus).
The percentage of patients with anti-pseudomonal antibodies
was comparable across the study (baseline: 19.6% of patients with
borderline titers and 17.6% positive; week 4: 21.6% and 13.4%;
week 28: 18.3% and 14.0%). Antibody status changed from
baseline to week 28 (or early termination visit) for 18 patients
(negative to borderline or positive: 7; borderline or positive to
negative: 11). The proportion of patients able to produce sputum
did not change substantially across the study. Genetic relatedness
(baseline vs. follow-up) was evaluated by PFGE for 59Pa isolates
from 20 patients [27]. The strain isolated during follow-up in
19 patients was identical to their original strain, while 2 post-
treatment isolates differed from the baseline strain for 1 patient
(Online Fig. 2).
4. Discussion
Consensus guidelines recommend early and aggressive treat-
ment to eradicate recently acquired Pa in CF patients although no
specific regimen is preferred [20]. Eradication rates of N75% over
a variety of time points have been reported, however differences
in study designs make direct comparisons difficult to perform
[12,18].
In the current study, pediatric patients with CF and newly
acquired Pa infection received a 28-day AZLI treatment course,
and respiratory cultures were obtained over a 24 week follow-up
period. In the primary efficacy evaluable set, 58.2% of the 79
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up period. Of the 101 patients who completed 4 weeks of AZLI
treatment, 89% and 75% were free of Pa at treatment end and
4 weeks post-treatment, respectively.
This was the first AZLI clinical trial enrolling CF patients with
Pa who were b6 years of age. Eradication rates were comparable
for the 3 age subgroups in this study (3 months to b2 years; 2 to
b6 years, 6 to b18 years), and plasma aztreonam levels for
patients b6 years were comparable to those reported previously
for patients ≥6 years old [22,29]. AZLI was well tolerated with
an adverse event profile consistent with the previously established
clinical trial experience [21–24]. Cough and other respiratory
eventswere themost common treatment-emergent adverse events.
Pyrexia was also common (14.3%), consistent with the incidence
of pyrexia (18%) observed in pediatric patients 6–17 years of age
in previous AZLI studies [30]. There were minimal changes in Pa
susceptibility to aztreonam or other antibiotics and concerning
changes were not observed in the appearance of other respiratory
pathogens. However, it is important to note that the majority of
cultures were throat swabs. This was consistent with the low
prevalence of sputum producers in the pediatric study population,
which had relatively well-preserved lung function. Fastidious
organisms, including fungal and mycobacterial pathogens, are
less easily recoverable from throat swab specimens. Further, the
sample size was too small to make firm statements on the
occurrence of uncommon pathogens.
The open-label design could also be considered a limitation
of the current study; however, the microbiological endpoint is
objective, and knowledge of study treatment would not have
affected the bacterial culture results. These objective culture
results allow comparisons between different studies for corre-
sponding time points in relation to the end of treatment. After 2
early placebo-controlled eradication studies, the second of which
was stopped early due to evidence of efficacy [5,10], subsequent
trials have been open-label without a placebo arm (note that
although the EPIC study [31] was placebo-controlled for oral
ciprofloxacin, all patients received open-label TIS). A random-
ized, blinded, placebo-controlled trial is difficult to recruit given
the accepted need and current consensus guidelines recommen-
dations for prompt Pa eradication treatment. Even postponing
treatment by onemonth was recently considered unethical bymost
investigators in the European Cystic Fibrosis Society-Clinical
Trials Network (ECFS-CTN), thereby limiting that alternative
design option.
Results from ALPINE compare favorably to those reported
in the “ELITE” study of TIS for Pa eradication [14]. Both studies
reported Pa culture-negative rates of ~90% immediately after
4 weeks of treatment; however, selection criteria differed for the
efficacy analysis study populations (Online Table 3). ELITE
randomized 71.5% of enrolled patients (n = 88/123), with most
exclusions (31/35) due to the presence of anti-pseudomonal
antibodies at baseline. The “efficacy” population for assessing
time to recurrence of Pa (primary endpoint) included randomized
patients who were culture-negative for Pa 1 month after TIS
treatment ended (n = 65/88; 73.9%). Patients with anti-
pseudomonal antibodies detectable at baseline were not excluded
from ALPINE analyses. Using a comparable subset of patients(without detectable anti-pseudomonal antibodies at baseline),
49/62 (79%) of ALPINE patients were culture-negative for Pa
4 weeks after AZLI treatment ended. The culture-negativity rates
maintained by this selected group of ALPINE patients at weeks
16 and 28 (85.7%, and 71.4%, respectively) were comparable to
those reported for ELITE at the corresponding time points (~82–
86%; ~76–82%; Online Table 4).
Another eradication study, “EPIC,” utilized a complex design
with repeated courses of TIS-containing treatment regimens and
patients receiving additional antibiotics for pulmonary exacerba-
tions were allowed to continue on the study, making direct
comparison to other studies more difficult [30]. The reported Pa
culture-positive rates, 10 weeks after the initial treatment course,
were 12% and 15% for the TIS + ciprofloxacin and TIS + placebo
groups, respectively. Taken together, results from ALPINE,
ELITE, and EPIC support a short treatment course (28 days) as
effective for initial eradication of Pa for most CF patients.
One challenge of eradication studies was highlighted in
results from the current study. All patients had cultures positive for
Pa within 30 days of screening (at local laboratories); however,
56% of these patients were culture-negative for Pa at baseline.
This patient subgroup demonstrated higher eradication rates over
the course of the study. Several factors likely contributed to the
lower number of culture-positive patients at baseline. The majority
of the baseline specimens collected were throat swabs, which can
have lower sensitivity than expectorated sputum for detecting Pa.
The inability of pediatric CF patients with new onset Pa infection
to produce sputum is not unexpected, as compared to adults
with more advanced lung disease. Further, Pa may be isolated
intermittently in CF patients with either new or chronic infection.
It should be noted that a comparable percentage of patients were
culture-positive for Pa (40%) at baseline in the EPIC study [31].
These factors highlight the inherent challenges in culturing
bacteria from respiratory tract samples, since detection may vary
with sampling technique. They also highlight the challenges in
interpreting results from eradication trials, in which Pa is only
detected intermittently and in which there are logistical factors
associated with transport of specimens to a central laboratory that
could potentially influence whether or not Pa is detected.
Study design issues in Pa eradication trials were addressed
in a recent workshop, which noted that negative cultures for
Pa should be considered to represent “apparent” eradication, due
to limitations in sampling respiratory specimens [32]. Another
recommendation was that the most appropriate primary endpoint
should reflect negative cultures obtained during the immediate
post-treatment timeframe (4–6 weeks), because it is biologically
implausible to expect a single course of inhaled antibiotics to
prevent long-term new acquisition of Pa. These study design
issues should be considered in developing future Pa eradication
protocols, and in evaluating results from previous studies.
In the current study, differences in spirometry results were
observed for patients with versus without successful Pa eradica-
tion after AZLI treatment. Patients remaining culture-negative for
Pa throughout the 24-week follow-up period also maintained
mean baseline FEV1 % predicted values, whereas patients with
recurrence of cultures positive for Pa, or those who received
anti-pseudomonal antibiotics in the follow-up period, experienced
118 H.A.W.M. Tiddens et al. / Journal of Cystic Fibrosis 14 (2015) 111–119decreases in mean FEV1 % predicted. This observation of the
impact of successful Pa eradication on pulmonary function
supports the rationale of the consensus guideline recommenda-
tions and current clinical practice of aggressive antibiotic
treatment for new onset Pa infection. Further, these data suggest
it will be important for future studies to identify which patients
are at risk for failing initial eradication therapies and determine
optimal treatment strategies for this group.
In conclusion, 28 days of AZLI treatment in pediatric patients
3 months to b18 years of age is both effective and well tolerated
in the treatment of early Pa pulmonary infection associated with
CF. The observed eradication rates are consistent with the success
rates reported in the literature for various antibiotic regimens,
including those utilizing other inhaled antibiotics.
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